FY2027 Earnings Forecast for IOVA Issued By HC Wainwright

Iovance Biotherapeutics, Inc. (NASDAQ:IOVA) – Analysts at HC Wainwright raised their FY2027 earnings per share (EPS) estimates for shares of Iovance Biotherapeutics in a research note issued on Friday, November 8th. HC Wainwright analyst J. Pantginis now expects that the biotechnology company will post earnings per share of $0.08 for the year, up from their previous forecast of $0.05. HC Wainwright currently has a “Buy” rating and a $32.00 target price on the stock. The consensus estimate for Iovance Biotherapeutics’ current full-year earnings is ($1.26) per share.

Several other equities research analysts also recently weighed in on the company. UBS Group started coverage on Iovance Biotherapeutics in a report on Thursday, October 24th. They issued a “buy” rating and a $17.00 price target on the stock. Piper Sandler downgraded Iovance Biotherapeutics from an “overweight” rating to a “neutral” rating and reduced their price target for the stock from $19.00 to $10.00 in a report on Monday, July 29th. Finally, StockNews.com upgraded Iovance Biotherapeutics to a “sell” rating in a report on Monday, August 12th. One analyst has rated the stock with a sell rating, one has issued a hold rating and eight have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $22.33.

Iovance Biotherapeutics Price Performance

NASDAQ:IOVA opened at $9.69 on Monday. The firm has a market capitalization of $2.71 billion, a price-to-earnings ratio of -6.50 and a beta of 0.60. Iovance Biotherapeutics has a 1 year low of $3.80 and a 1 year high of $18.33. The business has a 50 day simple moving average of $10.15 and a 200-day simple moving average of $9.78.

Iovance Biotherapeutics (NASDAQ:IOVA) last posted its quarterly earnings data on Thursday, November 7th. The biotechnology company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.31) by $0.03. The business had revenue of $58.56 million during the quarter, compared to analyst estimates of $53.54 million. Iovance Biotherapeutics had a negative return on equity of 60.50% and a negative net margin of 451.25%. During the same period last year, the company earned ($0.46) EPS.

Institutional Trading of Iovance Biotherapeutics

Institutional investors have recently made changes to their positions in the business. ORG Partners LLC acquired a new stake in Iovance Biotherapeutics during the 2nd quarter worth about $32,000. Quest Partners LLC lifted its holdings in shares of Iovance Biotherapeutics by 1,237.7% in the 2nd quarter. Quest Partners LLC now owns 5,003 shares of the biotechnology company’s stock valued at $40,000 after buying an additional 4,629 shares during the period. EverSource Wealth Advisors LLC acquired a new position in shares of Iovance Biotherapeutics in the 2nd quarter valued at about $58,000. Daiwa Securities Group Inc. lifted its holdings in shares of Iovance Biotherapeutics by 754.0% in the 2nd quarter. Daiwa Securities Group Inc. now owns 8,813 shares of the biotechnology company’s stock valued at $71,000 after buying an additional 7,781 shares during the period. Finally, ORG Wealth Partners LLC acquired a new position in shares of Iovance Biotherapeutics in the 3rd quarter valued at about $89,000. Institutional investors and hedge funds own 77.03% of the company’s stock.

About Iovance Biotherapeutics

Iovance Biotherapeutics, Inc, a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma.